Difference between revisions of "Rhabdomyosarcoma, pediatric - historical"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 4: Line 4:
 
</div>
 
</div>
 
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Rhabdomyosarcoma, pediatric|pediatric rhabdomyosarcoma page]] for current regimens.
 
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Rhabdomyosarcoma, pediatric|pediatric rhabdomyosarcoma page]] for current regimens.
 
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
Line 11: Line 10:
 
|}
 
|}
 
{{TOC limit|limit=4}}
 
{{TOC limit|limit=4}}
 
 
=Unstratified, all lines of therapy=
 
=Unstratified, all lines of therapy=
 
==Dactinomycin monotherapy {{#subobject:a9367b|Regimen=1}}==
 
==Dactinomycin monotherapy {{#subobject:a9367b|Regimen=1}}==
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:43c238|Variant=1}}===
 
===Regimen {{#subobject:43c238|Variant=1}}===
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
{| class="wikitable" style="width: 40%; text-align:center;"  
Line 24: Line 22:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Dactinomycin (Cosmegen)]]
 
*[[Dactinomycin (Cosmegen)]]
 
+
</div></div>
 
===References===
 
===References===
 
# Pinkel D. Actinomycin D in childhood cancer; a preliminary report. Pediatrics. 1959 Feb;23(2):342-7. [https://doi.org/10.1542/peds.23.2.342 link to original article] [https://pubmed.ncbi.nlm.nih.gov/13633349 PubMed]
 
# Pinkel D. Actinomycin D in childhood cancer; a preliminary report. Pediatrics. 1959 Feb;23(2):342-7. [https://doi.org/10.1542/peds.23.2.342 link to original article] [https://pubmed.ncbi.nlm.nih.gov/13633349 PubMed]
 
 
=High Risk, all lines of therapy=
 
=High Risk, all lines of therapy=
 
==COG D9802 VCPT Alternating with VAC Arm==
 
==COG D9802 VCPT Alternating with VAC Arm==
===Regimen, Irinotecan Window===
+
<div class="toccolours" style="background-color:#c8a2c8">
 +
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 +
!style="width: 33%"|Study
 +
!style="width: 33%"|Years of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://doi.org/10.1200/JCO.2006.07.1720 Pappo et al. 2007 (COG D9802)]
 +
|9/1999-11/2000
 +
| style="background-color:#91cf61" |Phase 2
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Protocol, Irinotecan Window===
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy, Week 0 (VCPT)====
 
====Chemotherapy, Week 0 (VCPT)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 48: Line 59:
 
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]]
 
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]]
 
====Chemotherapy, Week 2 Off Chemo====
 
====Chemotherapy, Week 2 Off Chemo====
 
 
====Chemotherapy, Week 3 (VCPT)====
 
====Chemotherapy, Week 3 (VCPT)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 64: Line 74:
 
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]]
 
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]]
 
====Chemotherapy, Week 5 Evaluation====
 
====Chemotherapy, Week 5 Evaluation====
 
+
</div></div><br>
===Regimen, Induction===
+
<div class="toccolours" style="background-color:#eeeeee">
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
+
===Induction===
!style="width: 33%"|Study
+
<div class="toccolours" style="background-color:#b3e2cd">
!style="width: 33%"|Years of enrollment
 
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|[https://doi.org/10.1200/JCO.2006.07.1720 Pappo et al. 2007 (COG D9802)]
 
|9/1999-11/2000
 
| style="background-color:#91cf61" |Phase 2
 
|-
 
|}
 
 
====Chemotherapy, Week 6 (VAC)====
 
====Chemotherapy, Week 6 (VAC)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 145: Line 147:
 
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
 
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
 
====Chemotherapy, Week 14 Evaluation====
 
====Chemotherapy, Week 14 Evaluation====
 
 
====Chemotherapy, Week 15 (Vincristine)====
 
====Chemotherapy, Week 15 (Vincristine)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 190: Line 191:
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
====Chemotherapy, Week 20 through 22 Off Chemo====
 
====Chemotherapy, Week 20 through 22 Off Chemo====
 
 
====Chemotherapy, Week 23 (VAC)====
 
====Chemotherapy, Week 23 (VAC)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 219: Line 219:
 
**Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
 
**Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
 
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
 
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
===Regimen, Continuation===
+
</div></div><br>
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Continuation===
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy, Week 26 (VCPT)====
 
====Chemotherapy, Week 26 (VCPT)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 235: Line 238:
 
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]]
 
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]]
 
====Chemotherapy, Week 28 Off Chemo====
 
====Chemotherapy, Week 28 Off Chemo====
 
 
====Chemotherapy, Week 29 (VAC)====
 
====Chemotherapy, Week 29 (VAC)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 254: Line 256:
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
====Chemotherapy, Week 30 through 31 Off Chemo====
 
====Chemotherapy, Week 30 through 31 Off Chemo====
 
 
====Chemotherapy, Week 32 (VCPT)====
 
====Chemotherapy, Week 32 (VCPT)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 292: Line 293:
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
====Chemotherapy, Week 36 through 37 Off Chemo====
 
====Chemotherapy, Week 36 through 37 Off Chemo====
 
 
====Chemotherapy, Week 38 (VCPT)====
 
====Chemotherapy, Week 38 (VCPT)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 308: Line 308:
 
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]]
 
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]]
 
====Chemotherapy, Week 40 Off Chemo====
 
====Chemotherapy, Week 40 Off Chemo====
 
 
====Chemotherapy, Week 41 (VAC)====
 
====Chemotherapy, Week 41 (VAC)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 327: Line 326:
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
====Chemotherapy, Week 42 through 43 Off Chemo====
 
====Chemotherapy, Week 42 through 43 Off Chemo====
 
 
====Chemotherapy, Week 44 Evaluation====
 
====Chemotherapy, Week 44 Evaluation====
 
+
</div></div></div>
 
===References===
 
===References===
# '''COG D9802:''' Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH. Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group. Journal of Clinical Oncology. 2007 Feb;25(4):362-369. [https://doi.org/10.1200/JCO.2006.07.1720 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00003955
+
# '''COG D9802:''' Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH. Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol. 2007 Feb 1;25(4):362-9. [https://doi.org/10.1200/JCO.2006.07.1720 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00003955
 
 
 
==COG D9802 VAC Alone Arm==
 
==COG D9802 VAC Alone Arm==
===Regimen, Irinotecan Window===
+
<div class="toccolours" style="background-color:#c8a2c8">
 +
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 +
!style="width: 33%"|Study
 +
!style="width: 33%"|Years of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://doi.org/10.1200/JCO.2006.07.1720 Pappo et al. 2007 (COG D9802)]
 +
|9/1999-11/2000
 +
| style="background-color:#91cf61" |Phase 2
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Protocol, Irinotecan Window===
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy, Week 0 (VCPT)====
 
====Chemotherapy, Week 0 (VCPT)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 350: Line 360:
 
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]]
 
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]]
 
====Chemotherapy, Week 2 Off Chemo====
 
====Chemotherapy, Week 2 Off Chemo====
 
 
====Chemotherapy, Week 3 (VCPT)====
 
====Chemotherapy, Week 3 (VCPT)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 366: Line 375:
 
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]]
 
**[[Irinotecan (Camptosar)]] to be given after [[Vincristine (Oncovin)]]
 
====Chemotherapy, Week 5 Evaluation====
 
====Chemotherapy, Week 5 Evaluation====
 
+
</div></div><br>
 
+
<div class="toccolours" style="background-color:#eeeeee">
===Regimen, Induction===
+
===Induction===
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy, Week 6 (VAC)====
 
====Chemotherapy, Week 6 (VAC)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 438: Line 448:
 
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
 
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
 
====Chemotherapy, Week 14 Evaluation====
 
====Chemotherapy, Week 14 Evaluation====
 
 
====Chemotherapy, Week 15 (Vincristine)====
 
====Chemotherapy, Week 15 (Vincristine)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 483: Line 492:
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
====Chemotherapy, Week 20 through 22 Off Chemo====
 
====Chemotherapy, Week 20 through 22 Off Chemo====
 
 
====Chemotherapy, Week 23 (VAC)====
 
====Chemotherapy, Week 23 (VAC)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 511: Line 519:
 
**Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
 
**Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
 
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
 
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
===Regimen, Continuation===
+
</div></div><br>
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Continuation===
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy, Week 26 (VAC)====
 
====Chemotherapy, Week 26 (VAC)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 535: Line 546:
 
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
 
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
 
====Chemotherapy, Week 28 Off Chemo====
 
====Chemotherapy, Week 28 Off Chemo====
 
 
====Chemotherapy, Week 29 (VAC)====
 
====Chemotherapy, Week 29 (VAC)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 554: Line 564:
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
====Chemotherapy, Week 30 through 31 Off Chemo====
 
====Chemotherapy, Week 30 through 31 Off Chemo====
 
 
====Chemotherapy, Week 32 (VAC)====
 
====Chemotherapy, Week 32 (VAC)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 600: Line 609:
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
====Chemotherapy, Week 36 through 37 Off Chemo====
 
====Chemotherapy, Week 36 through 37 Off Chemo====
 
 
====Chemotherapy, Week 38 (VAC)====
 
====Chemotherapy, Week 38 (VAC)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 619: Line 627:
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
====Chemotherapy, Week 39 through 40 Off Chemo====
 
====Chemotherapy, Week 39 through 40 Off Chemo====
 
 
====Chemotherapy, Week 41 (VAC)====
 
====Chemotherapy, Week 41 (VAC)====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 638: Line 645:
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
**Age < 1 year: 7.2 mg/m<sup>2</sup> IV infusion at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on day 1
 
====Chemotherapy, Week 42 through 43 Off Chemo====
 
====Chemotherapy, Week 42 through 43 Off Chemo====
 
 
====Chemotherapy, Week 44 Evaluation====
 
====Chemotherapy, Week 44 Evaluation====
 +
</div></div></div>
 
===References===
 
===References===
# '''COG D9802:''' Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH. Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group. Journal of Clinical Oncology. 2007 Feb;25(4):362-369. [https://doi.org/10.1200/JCO.2006.07.1720 link to original article] [https://pubmed-ncbi-nlm-nih-gov.proxy.library.vanderbilt.edu/17264331/ PubMed] NCT00003955
+
# '''COG D9802:''' Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH. Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol. 2007 Feb 1;25(4):362-9. [https://doi.org/10.1200/JCO.2006.07.1720 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00003955
 
 
 
=Low Risk, all lines of therapy=
 
=Low Risk, all lines of therapy=
 
==COG D9602 Subgroup A Clinical Group 1==
 
==COG D9602 Subgroup A Clinical Group 1==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen===
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
 
!style="width: 33%"|Study
 
!style="width: 33%"|Study
Line 655: Line 663:
 
|-
 
|-
 
|}
 
|}
===Regimen===
+
<div class="toccolours" style="background-color:#b3e2cd">
* Four 12-week cycles beginning on weeks 0, 12, 24, 36
 
 
====Chemotherapy, Week 0====
 
====Chemotherapy, Week 0====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 718: Line 725:
 
====Chemotherapy, Week 10 and 11 Off Chemo====
 
====Chemotherapy, Week 10 and 11 Off Chemo====
 
====Chemotherapy, Week 12 Evaluation====
 
====Chemotherapy, Week 12 Evaluation====
 +
'''12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36'''
 +
</div></div>
 
===References===
 
===References===
 
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995
 
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995
 
 
==COG D9602 Subgroup A Clinical Group 2==
 
==COG D9602 Subgroup A Clinical Group 2==
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
* Four 12-week cycles beginning on weeks 0, 12, 24, 36
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 +
!style="width: 33%"|Study
 +
!style="width: 33%"|Years of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ Raney et al. 2011 (IRSG D9602)]
 +
|9/1/1997-9/17/2004
 +
| style="background-color:#91cf61" |Phase 2
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy, Week 0====
 
====Chemotherapy, Week 0====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 783: Line 802:
 
====Chemotherapy, Week 10 and 11 Off Chemo====
 
====Chemotherapy, Week 10 and 11 Off Chemo====
 
====Chemotherapy, Week 12 Evaluation====
 
====Chemotherapy, Week 12 Evaluation====
 +
'''12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36'''
 +
</div></div>
 
===References===
 
===References===
 
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995
 
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995
 
 
==COG D9602 Subgroup A Clinical Group 3==
 
==COG D9602 Subgroup A Clinical Group 3==
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
* Four 12-week cycles beginning on weeks 0, 12, 24, 36
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 +
!style="width: 33%"|Study
 +
!style="width: 33%"|Years of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ Raney et al. 2011 (IRSG D9602)]
 +
|9/1/1997-9/17/2004
 +
| style="background-color:#91cf61" |Phase 2
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy, Week 0====
 
====Chemotherapy, Week 0====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 848: Line 879:
 
====Chemotherapy, Week 10 and 11 Off Chemo====
 
====Chemotherapy, Week 10 and 11 Off Chemo====
 
====Chemotherapy, Week 12 Evaluation====
 
====Chemotherapy, Week 12 Evaluation====
 +
'''12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36'''
 +
</div></div>
 
===References===
 
===References===
 
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995
 
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995
 
 
==COG D9602 Subgroup B Clinical Group 1==
 
==COG D9602 Subgroup B Clinical Group 1==
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
* Four 12-week cycles beginning on weeks 0, 12, 24, 36
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 +
!style="width: 33%"|Study
 +
!style="width: 33%"|Years of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ Raney et al. 2011 (IRSG D9602)]
 +
|9/1/1997-9/17/2004
 +
| style="background-color:#91cf61" |Phase 2
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy, Week 0====
 
====Chemotherapy, Week 0====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 955: Line 998:
 
====Chemotherapy, Week 10 and 11 Off Chemo====
 
====Chemotherapy, Week 10 and 11 Off Chemo====
 
====Chemotherapy, Week 12 Evaluation====
 
====Chemotherapy, Week 12 Evaluation====
 +
'''12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36'''
 +
</div></div>
 
===References===
 
===References===
 
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995
 
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995
 
 
==COG D9602 Subgroup B Clinical Group 2==
 
==COG D9602 Subgroup B Clinical Group 2==
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
* Four 12-week cycles beginning on weeks 0, 12, 24, 36
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 +
!style="width: 33%"|Study
 +
!style="width: 33%"|Years of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ Raney et al. 2011 (IRSG D9602)]
 +
|9/1/1997-9/17/2004
 +
| style="background-color:#91cf61" |Phase 2
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy, Week 0====
 
====Chemotherapy, Week 0====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 1,009: Line 1,064:
 
====Radiotherapy, Week 3====
 
====Radiotherapy, Week 3====
 
*[[External beam radiotherapy]] 36 Gy given once daily in 20 divided fractions
 
*[[External beam radiotherapy]] 36 Gy given once daily in 20 divided fractions
 
 
====Chemotherapy, Week 4====
 
====Chemotherapy, Week 4====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 1,061: Line 1,115:
 
====Chemotherapy, Week 10 and 11 Off Chemo====
 
====Chemotherapy, Week 10 and 11 Off Chemo====
 
====Chemotherapy, Week 12 Evaluation====
 
====Chemotherapy, Week 12 Evaluation====
 +
'''12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36'''
 +
</div></div>
 
===References===
 
===References===
 
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995
 
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995
 
 
==COG D9602 Subgroup B Clinical Group 3==
 
==COG D9602 Subgroup B Clinical Group 3==
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
* Four 12-week cycles beginning on weeks 0, 12, 24, 36
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 +
!style="width: 33%"|Study
 +
!style="width: 33%"|Years of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ Raney et al. 2011 (IRSG D9602)]
 +
|9/1/1997-9/17/2004
 +
| style="background-color:#91cf61" |Phase 2
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy, Week 0====
 
====Chemotherapy, Week 0====
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 1,167: Line 1,232:
 
====Chemotherapy, Week 10 and 11 Off Chemo====
 
====Chemotherapy, Week 10 and 11 Off Chemo====
 
====Chemotherapy, Week 12 Evaluation====
 
====Chemotherapy, Week 12 Evaluation====
 
+
'''12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36'''
 +
</div></div>
 
===References===
 
===References===
 
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995
 
#'''IRSG D9602:''' Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. [https://doi.org/10.1200/JCO.2010.30.4469 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083999/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/17264331/ PubMed] NCT00002995
 
 
[[Category:Bone sarcomas]]
 
[[Category:Bone sarcomas]]
 
[[Category:Historical regimens]]
 
[[Category:Historical regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Pediatric solid tumors]]
 
[[Category:Pediatric solid tumors]]

Revision as of 02:18, 3 March 2023

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the pediatric rhabdomyosarcoma page for current regimens.

1 regimens on this page
1 variants on this page


Unstratified, all lines of therapy

Dactinomycin monotherapy

Regimen

Study Evidence
Pinkel 1959 Pilot

References

  1. Pinkel D. Actinomycin D in childhood cancer; a preliminary report. Pediatrics. 1959 Feb;23(2):342-7. link to original article PubMed

High Risk, all lines of therapy

COG D9802 VCPT Alternating with VAC Arm

Study Years of enrollment Evidence
Pappo et al. 2007 (COG D9802) 9/1999-11/2000 Phase 2

Protocol, Irinotecan Window

Chemotherapy, Week 0 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 1 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 2 Off Chemo

Chemotherapy, Week 3 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 4 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 5 Evaluation


Induction

Chemotherapy, Week 6 (VAC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 6

Chemotherapy, Week 7 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 8 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 9 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 10 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 11 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 12 (VAC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 12

Chemotherapy, Week 13 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 14 Evaluation

Chemotherapy, Week 15 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 16 (VC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 16

Chemotherapy, Week 17 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 18 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 19 (VC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 19

Chemotherapy, Week 20 through 22 Off Chemo

Chemotherapy, Week 23 (VAC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 23

Chemotherapy, Week 24 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 25 (Eval/Vincristine)

  • Evaluation Week
  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Continuation

Chemotherapy, Week 26 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 27 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 28 Off Chemo

Chemotherapy, Week 29 (VAC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 29

Chemotherapy, Week 30 through 31 Off Chemo

Chemotherapy, Week 32 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 33 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 34 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 35 (VAC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 35

Chemotherapy, Week 36 through 37 Off Chemo

Chemotherapy, Week 38 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 39 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 40 Off Chemo

Chemotherapy, Week 41 (VAC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 41

Chemotherapy, Week 42 through 43 Off Chemo

Chemotherapy, Week 44 Evaluation

References

  1. COG D9802: Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH. Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol. 2007 Feb 1;25(4):362-9. link to original article PubMed NCT00003955

COG D9802 VAC Alone Arm

Study Years of enrollment Evidence
Pappo et al. 2007 (COG D9802) 9/1999-11/2000 Phase 2

Protocol, Irinotecan Window

Chemotherapy, Week 0 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 1 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 2 Off Chemo

Chemotherapy, Week 3 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 4 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 5 Evaluation


Induction

Chemotherapy, Week 6 (VAC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 6

Chemotherapy, Week 7 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 8 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 9 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 10 (VCPT)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 40 mg/day) IV over 60 minutes once per day on days 1 through 5

Chemotherapy, Week 11 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 12 (VAC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 12

Chemotherapy, Week 13 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 14 Evaluation

Chemotherapy, Week 15 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 16 (VC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 16

Chemotherapy, Week 17 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 18 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 19 (VC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 19

Chemotherapy, Week 20 through 22 Off Chemo

Chemotherapy, Week 23 (VAC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 23

Chemotherapy, Week 24 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 25 (Evaluation/Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Continuation

Chemotherapy, Week 26 (VAC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 26

Chemotherapy, Week 27 (VCR)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 28 Off Chemo

Chemotherapy, Week 29 (VAC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 29

Chemotherapy, Week 30 through 31 Off Chemo

Chemotherapy, Week 32 (VAC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 32

Chemotherapy, Week 33 (VCR)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 34 (Vincristine)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 35 (VAC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 35

Chemotherapy, Week 36 through 37 Off Chemo

Chemotherapy, Week 38 (VAC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 38

Chemotherapy, Week 39 through 40 Off Chemo

Chemotherapy, Week 41 (VAC)

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 41

Chemotherapy, Week 42 through 43 Off Chemo

Chemotherapy, Week 44 Evaluation

References

  1. COG D9802: Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH. Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol. 2007 Feb 1;25(4):362-9. link to original article PubMed NCT00003955

Low Risk, all lines of therapy

COG D9602 Subgroup A Clinical Group 1

Regimen

Study Years of enrollment Evidence
Raney et al. 2011 (IRSG D9602) 9/1/1997-9/17/2004 Phase 2

Chemotherapy, Week 0

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1

Chemotherapy, Week 1

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 2

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 3

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • No External beam radiotherapy

Chemotherapy, Week 4

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 5

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 6

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1

Chemotherapy, Week 7

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 8

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 9

  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1

Chemotherapy, Week 10 and 11 Off Chemo

Chemotherapy, Week 12 Evaluation

12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36

References

  1. IRSG D9602: Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. link to original article link to PMC article PubMed NCT00002995

COG D9602 Subgroup A Clinical Group 2

Regimen

Study Years of enrollment Evidence
Raney et al. 2011 (IRSG D9602) 9/1/1997-9/17/2004 Phase 2

Chemotherapy, Week 0

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1

Chemotherapy, Week 1

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 2

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 3

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1

Radiotherapy, Week 3

Chemotherapy, Week 4

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 5

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 6

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 7

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 8

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 9

  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1

Chemotherapy, Week 10 and 11 Off Chemo

Chemotherapy, Week 12 Evaluation

12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36

References

  1. IRSG D9602: Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. link to original article link to PMC article PubMed NCT00002995

COG D9602 Subgroup A Clinical Group 3

Regimen

Study Years of enrollment Evidence
Raney et al. 2011 (IRSG D9602) 9/1/1997-9/17/2004 Phase 2

Chemotherapy, Week 0

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1

Chemotherapy, Week 1

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 2

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 3

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1

Radiotherapy, Week 3

Chemotherapy, Week 4

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 5

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 6

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 7

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 8

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 9

  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1

Chemotherapy, Week 10 and 11 Off Chemo

Chemotherapy, Week 12 Evaluation

12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36

References

  1. IRSG D9602: Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. link to original article link to PMC article PubMed NCT00002995

COG D9602 Subgroup B Clinical Group 1

Regimen

Study Years of enrollment Evidence
Raney et al. 2011 (IRSG D9602) 9/1/1997-9/17/2004 Phase 2

Chemotherapy, Week 0

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 0

  • Mesna (Mesnex) by the following age-based criteria:
  • Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL

Chemotherapy, Week 1

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 2

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 3

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 3

Chemotherapy, Week 4

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 5

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 6

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 6

  • Mesna (Mesnex) by the following age-based criteria:
  • Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL

Chemotherapy, Week 7

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 8

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 9

  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 9

  • Mesna (Mesnex) by the following age-based criteria:
  • Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after AC completion and continued once daily for 10 days or until ANC > 2000/μL

Chemotherapy, Week 10 and 11 Off Chemo

Chemotherapy, Week 12 Evaluation

12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36

References

  1. IRSG D9602: Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. link to original article link to PMC article PubMed NCT00002995

COG D9602 Subgroup B Clinical Group 2

Regimen

Study Years of enrollment Evidence
Raney et al. 2011 (IRSG D9602) 9/1/1997-9/17/2004 Phase 2

Chemotherapy, Week 0

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 0

  • Mesna (Mesnex) by the following age-based criteria:
  • Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL

Chemotherapy, Week 1

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 2

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 3

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 3

  • Mesna (Mesnex) by the following age-based criteria:
  • Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL

Radiotherapy, Week 3

Chemotherapy, Week 4

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 5

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 6

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 6

  • Mesna (Mesnex) by the following age-based criteria:
  • Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL

Chemotherapy, Week 7

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 8

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 9

  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 9

  • Mesna (Mesnex) by the following age-based criteria:
  • Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after AC completion and continued once daily for 10 days or until ANC > 2000/μL

Chemotherapy, Week 10 and 11 Off Chemo

Chemotherapy, Week 12 Evaluation

12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36

References

  1. IRSG D9602: Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. link to original article link to PMC article PubMed NCT00002995

COG D9602 Subgroup B Clinical Group 3

Regimen

Study Years of enrollment Evidence
Raney et al. 2011 (IRSG D9602) 9/1/1997-9/17/2004 Phase 2

Chemotherapy, Week 0

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 0

  • Mesna (Mesnex) by the following age-based criteria:
  • Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL

Chemotherapy, Week 1

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 2

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 3

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 3

  • Mesna (Mesnex) by the following age-based criteria:
  • Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL

Radiotherapy, Week 3

Chemotherapy, Week 4

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 5

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 6

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 6

  • Mesna (Mesnex) by the following age-based criteria:
  • Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after VAC completion and continued once daily for 10 days or until ANC > 2000/μL

Chemotherapy, Week 7

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 8

  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Chemotherapy, Week 9

  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 2.2 g/m2 IV infusion over 30 to 60 minutes once per day on day 1
    • Age ≥ 1 year: 73 mg/kg IV infusion over 30 to 60 minutes once on day 1
    • Age < 1 year: 36 mg/kg IV infusion over 30 to 60 minutes once on day 1

Supportive Medications, Week 9

  • Mesna (Mesnex) by the following age-based criteria:
  • Filgrastim (Neupogen) 5 mcg/kg SubQ or IV (per institutional policy) once daily starting 24 hours after AC completion and continued once daily for 10 days or until ANC > 2000/μL

Chemotherapy, Week 10 and 11 Off Chemo

Chemotherapy, Week 12 Evaluation

12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36

References

  1. IRSG D9602: Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 1;29(10):1312-8. link to original article link to PMC article PubMed NCT00002995